世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

欧州セルライト治療市場予測 2023-2032

欧州セルライト治療市場予測 2023-2032


EUROPE CELLULITE TREATMENT MARKET FORECAST 2023-2032

主な調査結果 欧州のセルライト治療市場は、2023-2032年の予測期間中にCAGR 9.47％で成長すると予想されています。この地域市場の成長の原動力は、高齢化社会の進展に伴う肥満の急増、先進技術の採用や新製品の... もっと見る

　

　

出版社 出版年月 電子版価格 納期 ページ数 言語
Inkwood Research
インクウッドリサーチ 		2023年3月4日 US$1,600
シングルユーザライセンス（印刷不可）
ライセンス・価格情報
注文方法はこちら 		2-3営業日以内 153 英語

　

サマリー

主な調査結果
欧州のセルライト治療市場は、2023-2032年の予測期間中にCAGR 9.47％で成長すると予想されています。この地域市場の成長の原動力は、高齢化社会の進展に伴う肥満の急増、先進技術の採用や新製品の発売の増加、低侵襲・非侵襲の施術への傾倒の高まりです。
市場インサイト
欧州セルライト治療市場の成長評価は、フランス、イタリア、ベルギー、ドイツ、英国、ポーランド、その他の欧州の評価を含んでいます。フランスでは、高いファッション性と美意識が、今後数年間にわたりセルライト治療の需要を促進すると予想されます。さらに、同国では美容意識の高まりとともに形成外科医が急増しているため、セルライト治療の施術数がさらに増加し、市場の成長に寄与すると考えられています。
経済協力開発機構（OECD）のデータによると、フランスでは10人に1人が肥満である一方、40％近くが過体重である。また、世界銀行のデータによると、同国の人口の約21％が65歳以上の高齢者です。肥満がセルライトの原因となり、年齢とともに増加することから、フランスでは肥満の急増がセルライト治療へのニーズをさらに高めると予想されます。その結果、これらの要因は、予測期間中に欧州の市場成長を促進する上で重要な役割を果たすと予測されます。
競合他社の洞察
市場で事業を展開している主な企業は、Zimmer MedizinSysteme、Inceler Medikal Co Ltd、Sinclair Pharmaなどです。
当社のレポート提供内容は以下の通りです：
- 市場全体の主要な調査結果を探る
- 市場ダイナミクス（推進要因、抑制要因、機会、課題）の戦略的な内訳説明
- すべてのセグメント、サブセグメント、地域の3年間の過去データとともに、最低9年間の市場予測
- 市場セグメンテーション：主要なセグメントを徹底的に評価し、その市場規模を推定します。
- 地域別分析：地域および国別セグメントの評価とその市場占有率
- 主要な分析ポーターのファイブフォース分析、ベンダーランドスケープ、オポチュニティマトリックス、主要な購買基準など。
- 競合環境は、主要企業を要因や市場シェアなどに基づいて理論的に説明するものです。
- 企業プロファイリング：詳細な会社概要、提供する製品/サービス、SCOT分析、最近の戦略的展開など。


ページTOPに戻る


目次

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. RISING BEAUTY CONSCIOUSNESS
2.5.2. GROWING PREFERENCE TOWARDS NON-INVASIVE PROCEDURES
2.5.3. RAPID TECHNOLOGICAL ADVANCEMENTS TO PROMOTE MARKET GROWTH
2.5.4. RAPIDLY CHANGING LIFESTYLES LEADING TO OBESITY
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING DEMAND FOR AESTHETIC AND COSMETIC PROCEDURES
3.1.2. RISING CASES OF OBESITY
3.1.3. RAPIDLY BOOMING MEDICAL TOURISM INDUSTRY
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF ADVANCED CELLULITE TREATMENT
3.2.2. SIDE EFFECTS POST-TREATMENT
3.2.3. LACK OF AWARENESS
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY TECHNOLOGY TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. PRODUCT DEVELOPMENT
4.7.3. MARKETING AND DISTRIBUTION
4.7.4. POST-SALES MONITORING
4.8. KEY BUYING CRITERIA
4.8.1. COST
4.8.2. BRAND REPUTATION
4.8.3. USABILITY
5. MARKET BY PROCEDURE
5.1. NON-INVASIVE
5.2. MINIMALLY INVASIVE
5.3. TOPICAL
6. MARKET BY TYPE
6.1. SOFT CELLULITE
6.2. HARD CELLULITE
6.3. EDEMATOUS CELLULITE
7. MARKET BY END-USER
7.1. HOSPITALS
7.2. CLINICS AND BEAUTY CENTERS
7.3. OTHER END-USERS
8. GEOGRAPHICAL ANALYSIS
8.1. EUROPE
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. EUROPE CELLULITE TREATMENT MARKET DRIVERS
8.1.3. EUROPE CELLULITE TREATMENT MARKET CHALLENGES
8.1.4. EUROPE CELLULITE TREATMENT MARKET REGULATORY FRAMEWORK
8.1.5. KEY PLAYERS IN EUROPE CELLULITE TREATMENT MARKET
8.1.6. COUNTRY ANALYSIS
8.1.6.1. UNITED KINGDOM
8.1.6.1.1. UNITED KINGDOM CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.2. GERMANY
8.1.6.2.1. GERMANY CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.3. FRANCE
8.1.6.3.1. FRANCE CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.4. ITALY
8.1.6.4.1. ITALY CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.5. BELGIUM
8.1.6.5.1. BELGIUM CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.6. POLAND
8.1.6.6.1. POLAND CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.7. REST OF EUROPE
8.1.6.7.1. REST OF EUROPE CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. ABBVIE INC
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. FINANCIAL ANALYSIS
9.2.1.3. PRODUCTS / SERVICES LIST
9.2.1.4. STRENGTHS & CHALLENGES
9.2.2. ALMA LASERS
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCTS / SERVICES LIST
9.2.3. BAUSCH HEALTH COMPANIES INC.
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. FINANCIAL ANALYSIS
9.2.3.3. PRODUCTS / SERVICES LIST
9.2.3.4. STRENGTHS & CHALLENGES
9.2.4. CANDELA CORPORATION
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCTS / SERVICES LIST
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. CUTERA INC
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. FINANCIAL ANALYSIS
9.2.5.3. PRODUCTS / SERVICES LIST
9.2.5.4. STRENGTHS & CHALLENGES
9.2.6. CYNOSURE LLC
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. PRODUCTS / SERVICES LIST
9.2.6.3. STRENGTHS & CHALLENGES
9.2.7. ENDO INTERNATIONAL PLC
9.2.7.1. COMPANY OVERVIEW
9.2.7.2. FINANCIAL ANALYSIS
9.2.7.3. PRODUCTS / SERVICES LIST
9.2.7.4. STRENGTHS & CHALLENGES
9.2.8. GALDERMA SA
9.2.8.1. COMPANY OVERVIEW
9.2.8.2. PRODUCTS / SERVICES LIST
9.2.8.3. STRENGTHS & CHALLENGES
9.2.9. INCELER MEDIKAL CO LTD
9.2.9.1. COMPANY OVERVIEW
9.2.9.2. PRODUCTS / SERVICES LIST
9.2.9.3. STRENGTHS & CHALLENGES
9.2.10. JOHNSON & JOHNSON
9.2.10.1. COMPANY OVERVIEW
9.2.10.2. FINANCIAL ANALYSIS
9.2.10.3. PRODUCTS / SERVICES LIST
9.2.10.4. STRENGTHS & CHALLENGES
9.2.11. MERZ PHARMA GMBH & CO KGAA
9.2.11.1. COMPANY OVERVIEW
9.2.11.2. PRODUCTS / SERVICES LIST
9.2.11.3. STRENGTHS & CHALLENGES
9.2.12. NUBWAY CO LTD
9.2.12.1. COMPANY OVERVIEW
9.2.12.2. PRODUCTS / SERVICES LIST
9.2.13. SIENTRA INC
9.2.13.1. COMPANY OVERVIEW
9.2.13.2. FINANCIAL ANALYSIS
9.2.13.3. PRODUCTS / SERVICES LIST
9.2.13.4. STRENGTHS & CHALLENGES
9.2.14. SINCLAIR PHARMA
9.2.14.1. COMPANY OVERVIEW
9.2.14.2. PRODUCTS / SERVICES LIST
9.2.15. ZIMMER MEDIZINSYSTEME
9.2.15.1. COMPANY OVERVIEW
9.2.15.2. PRODUCTS / SERVICES LIST
9.2.15.3. STRENGTHS & CHALLENGES

ページTOPに戻る



図表リスト

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – CELLULITE TREATMENT
TABLE 2: EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: EUROPE CELLULITE TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: EUROPE CELLULITE TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: EUROPE CELLULITE TREATMENT MARKET, BY END-USER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: EUROPE CELLULITE TREATMENT MARKET, BY END-USER, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: EUROPE CELLULITE TREATMENT MARKET REGULATORY FRAMEWORK
TABLE 11: LEADING PLAYERS OPERATING IN EUROPE CELLULITE TREATMENT MARKET
TABLE 12: LIST OF ACQUISITIONS
TABLE 13: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 14: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 15: LIST OF EXPANSIONS & DIVESTITURES

　

ページTOPに戻る


　

Summary

KEY FINDINGS
The Europe cellulite treatment market is expected to grow with a CAGR of 9.47% during the forecasting period of 2023-2032. The regional market’s growth is fueled by the surge in the occurrence of obesity, coupled with the rise in the aging population, the increasing adoption of advanced technologies as well as the launch of new products, and the growing inclination towards minimally invasive and non-invasive procedures.
MARKET INSIGHTS
The Europe cellulite treatment market growth assessment entails the evaluation of France, Italy, Belgium, Germany, the United Kingdom, Poland, and Rest of Europe. The high fashion, as well as aesthetic consciousness in France, is anticipated to fuel the demand for cellulite treatments over the upcoming years. Moreover, the surging availability of plastic surgeons as well as the growing beauty consciousness in the country, is set to further fuel the number of cellulite treatment procedures, thus contributing to market growth.
According to the data issued by the Organization for Economic Cooperation and Development (OECD), while around 1 in 10 people in France are obese, nearly 40% are overweight. Additionally, as per World Bank data, approximately 21% of the country’s population was aged 65 years and over. Since excess weight leads to cellulite and obesity increases with age, the surging incidence of obesity is further expected to drive the need for cellulite treatments in France. As a result, these factors are projected to play an essential role in propelling market growth in Europe during the forecast period.
COMPETITIVE INSIGHTS
Major companies operating in the market are Zimmer MedizinSysteme, Inceler Medikal Co Ltd, Sinclair Pharma, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. RISING BEAUTY CONSCIOUSNESS
2.5.2. GROWING PREFERENCE TOWARDS NON-INVASIVE PROCEDURES
2.5.3. RAPID TECHNOLOGICAL ADVANCEMENTS TO PROMOTE MARKET GROWTH
2.5.4. RAPIDLY CHANGING LIFESTYLES LEADING TO OBESITY
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING DEMAND FOR AESTHETIC AND COSMETIC PROCEDURES
3.1.2. RISING CASES OF OBESITY
3.1.3. RAPIDLY BOOMING MEDICAL TOURISM INDUSTRY
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF ADVANCED CELLULITE TREATMENT
3.2.2. SIDE EFFECTS POST-TREATMENT
3.2.3. LACK OF AWARENESS
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY TECHNOLOGY TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. PRODUCT DEVELOPMENT
4.7.3. MARKETING AND DISTRIBUTION
4.7.4. POST-SALES MONITORING
4.8. KEY BUYING CRITERIA
4.8.1. COST
4.8.2. BRAND REPUTATION
4.8.3. USABILITY
5. MARKET BY PROCEDURE
5.1. NON-INVASIVE
5.2. MINIMALLY INVASIVE
5.3. TOPICAL
6. MARKET BY TYPE
6.1. SOFT CELLULITE
6.2. HARD CELLULITE
6.3. EDEMATOUS CELLULITE
7. MARKET BY END-USER
7.1. HOSPITALS
7.2. CLINICS AND BEAUTY CENTERS
7.3. OTHER END-USERS
8. GEOGRAPHICAL ANALYSIS
8.1. EUROPE
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. EUROPE CELLULITE TREATMENT MARKET DRIVERS
8.1.3. EUROPE CELLULITE TREATMENT MARKET CHALLENGES
8.1.4. EUROPE CELLULITE TREATMENT MARKET REGULATORY FRAMEWORK
8.1.5. KEY PLAYERS IN EUROPE CELLULITE TREATMENT MARKET
8.1.6. COUNTRY ANALYSIS
8.1.6.1. UNITED KINGDOM
8.1.6.1.1. UNITED KINGDOM CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.2. GERMANY
8.1.6.2.1. GERMANY CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.3. FRANCE
8.1.6.3.1. FRANCE CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.4. ITALY
8.1.6.4.1. ITALY CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.5. BELGIUM
8.1.6.5.1. BELGIUM CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.6. POLAND
8.1.6.6.1. POLAND CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
8.1.6.7. REST OF EUROPE
8.1.6.7.1. REST OF EUROPE CELLULITE TREATMENT MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. ABBVIE INC
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. FINANCIAL ANALYSIS
9.2.1.3. PRODUCTS / SERVICES LIST
9.2.1.4. STRENGTHS & CHALLENGES
9.2.2. ALMA LASERS
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCTS / SERVICES LIST
9.2.3. BAUSCH HEALTH COMPANIES INC.
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. FINANCIAL ANALYSIS
9.2.3.3. PRODUCTS / SERVICES LIST
9.2.3.4. STRENGTHS & CHALLENGES
9.2.4. CANDELA CORPORATION
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCTS / SERVICES LIST
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. CUTERA INC
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. FINANCIAL ANALYSIS
9.2.5.3. PRODUCTS / SERVICES LIST
9.2.5.4. STRENGTHS & CHALLENGES
9.2.6. CYNOSURE LLC
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. PRODUCTS / SERVICES LIST
9.2.6.3. STRENGTHS & CHALLENGES
9.2.7. ENDO INTERNATIONAL PLC
9.2.7.1. COMPANY OVERVIEW
9.2.7.2. FINANCIAL ANALYSIS
9.2.7.3. PRODUCTS / SERVICES LIST
9.2.7.4. STRENGTHS & CHALLENGES
9.2.8. GALDERMA SA
9.2.8.1. COMPANY OVERVIEW
9.2.8.2. PRODUCTS / SERVICES LIST
9.2.8.3. STRENGTHS & CHALLENGES
9.2.9. INCELER MEDIKAL CO LTD
9.2.9.1. COMPANY OVERVIEW
9.2.9.2. PRODUCTS / SERVICES LIST
9.2.9.3. STRENGTHS & CHALLENGES
9.2.10. JOHNSON & JOHNSON
9.2.10.1. COMPANY OVERVIEW
9.2.10.2. FINANCIAL ANALYSIS
9.2.10.3. PRODUCTS / SERVICES LIST
9.2.10.4. STRENGTHS & CHALLENGES
9.2.11. MERZ PHARMA GMBH & CO KGAA
9.2.11.1. COMPANY OVERVIEW
9.2.11.2. PRODUCTS / SERVICES LIST
9.2.11.3. STRENGTHS & CHALLENGES
9.2.12. NUBWAY CO LTD
9.2.12.1. COMPANY OVERVIEW
9.2.12.2. PRODUCTS / SERVICES LIST
9.2.13. SIENTRA INC
9.2.13.1. COMPANY OVERVIEW
9.2.13.2. FINANCIAL ANALYSIS
9.2.13.3. PRODUCTS / SERVICES LIST
9.2.13.4. STRENGTHS & CHALLENGES
9.2.14. SINCLAIR PHARMA
9.2.14.1. COMPANY OVERVIEW
9.2.14.2. PRODUCTS / SERVICES LIST
9.2.15. ZIMMER MEDIZINSYSTEME
9.2.15.1. COMPANY OVERVIEW
9.2.15.2. PRODUCTS / SERVICES LIST
9.2.15.3. STRENGTHS & CHALLENGES

ページTOPに戻る



List of Tables/Graphs

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – CELLULITE TREATMENT
TABLE 2: EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: EUROPE CELLULITE TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: EUROPE CELLULITE TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: EUROPE CELLULITE TREATMENT MARKET, BY END-USER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: EUROPE CELLULITE TREATMENT MARKET, BY END-USER, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: EUROPE CELLULITE TREATMENT MARKET REGULATORY FRAMEWORK
TABLE 11: LEADING PLAYERS OPERATING IN EUROPE CELLULITE TREATMENT MARKET
TABLE 12: LIST OF ACQUISITIONS
TABLE 13: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 14: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 15: LIST OF EXPANSIONS & DIVESTITURES

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

Inkwood Research社の
Fatal error: Uncaught TypeError: Cannot access offset of type string on string in /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/58b4bde6a9738f3389cd7dea7f4ef5c62fdc6c54_0.file.auto_report.tpl.php:630 Stack trace: #0 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_resource_base.php(123): content_68d51da90169e8_18903235() #1 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_compiled.php(114): Smarty_Template_Resource_Base->getRenderedTemplateCode() #2 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(216): Smarty_Template_Compiled->render() #3 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(385): Smarty_Internal_Template->render() #4 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/f20300271f4eb0fb4a2cf788aaabb06be5646d19_0.file.frame-FULL.tpl.php(278): Smarty_Internal_Template->_subTemplateRender() #5 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_resource_base.php(123): content_68b0f61a4d9868_07068969() #6 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_compiled.php(114): Smarty_Template_Resource_Base->getRenderedTemplateCode() #7 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(216): Smarty_Template_Compiled->render() #8 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_templatebase.php(238): Smarty_Internal_Template->render() #9 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_templatebase.php(134): Smarty_Internal_TemplateBase->_execute() #10 /var/www/vhosts/dri.co.jp/httpdocs/auto/show_report.php(776): Smarty_Internal_TemplateBase->display() #11 {main} thrown in /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/58b4bde6a9738f3389cd7dea7f4ef5c62fdc6c54_0.file.auto_report.tpl.php on line 630